Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Debiopharm begins Phase I Study of Debio 1450
The double-blind and placebo-controlled study will evaluate the safety, tolerability, and pharmacokinetics of single oral doses of Debio 1450 in healthy subjects. Debio 1450 is an anti-infective agent
The double-blind and placebo-controlled study will evaluate the safety, tolerability, and pharmacokinetics of single oral doses of Debio 1450 in healthy subjects. Debio 1450 is an anti-infective agent
The ceftolozane/tazobactam is being developed to treat complicated urinary tract and intra-abdominal infections. The submission of NDA is supported by the positive data from two pivotal Phase 3
The decision was taken as the studies showed that orteronel plus prednisone could extend the time patients lived before their cancer progressed but failed to extend overall survival
Under the deal, Cipher has granted Andrómaco the exclusive right to market, sell and distribute its isotretinoin capsules in the country. After securing regulatory approval, it is expected
Under the deal, the company will be working with nanoRANCH’s Dan Dimitrijevich to create new treatment delivery methods using a combination of nanoRANCH technology and CRYO’s clinically processed
Cellectis said that its CAR-T technology offers an allogeneic approach in developing CAR-T therapies that are distinct from other autologous approaches. As part of the deal, Pfizer will
VX-787 is an influenza A-specific, oral polymerase inhibitor designed to directly inhibit replication of the influenza A virus, including recent H1 and H5 influenza strains, based on in-vitro
Under the deal, Medison will market Glybera, uniQure’s gene therapy product for the treatment of lipoprotein lipase deficiency (LPLD), in Israel and the Palestinian Authority. Medison will also
The trial is designed to assess the safety and efficacy of Pyridorin in slowing disease progression in patients with diabetic nephropathy. NephroGenex CEO Pierre Legault said with the
Being developed for the treatment of several cancer indications including patients with recurrent glioblastoma, DNX-2401 is claimed to be the most potent and effective oncolytic virus delivered to